ThromboGenics NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.07.24	Oxurion Share Consolidation (GlobeNewswire)
24.07.24	Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 (GlobeNewswire)
19.07.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
18.07.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
11.07.24	Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (GlobeNewswire)
08.07.24	Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production (GlobeNewswire)
04.07.24	Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024 (GlobeNewswire)
07.06.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
04.06.24	Oxurion Announces Extraordinary General Shareholders’ Meeting (GlobeNewswire)
27.05.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
23.05.24	Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 (GlobeNewswire)
23.05.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
16.05.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
14.05.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
13.05.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
06.05.24	Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD (GlobeNewswire)
25.04.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
15.04.24	Publication Annual Report – Annual Shareholders' Meeting (GlobeNewswire)
11.04.24	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
10.04.24	Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up (GlobeNewswire)
05.04.24	Postponement Annual Shareholders Meeting - Amendment financial calendar (GlobeNewswire)
28.03.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
27.03.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version (GlobeNewswire)
26.03.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas (GlobeNewswire)
25.03.24	OXURION announces its presence at the Paris SmallCap event on March 28, 2024. (GlobeNewswire)
22.03.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
21.03.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas (GlobeNewswire)
13.03.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
07.03.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
05.03.24	Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up (GlobeNewswire)
04.03.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas (GlobeNewswire)
22.01.24	Oxurion Announces New Strategic Orientation to De-risk and Diversify (GlobeNewswire)
19.01.24	Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas (GlobeNewswire)
17.01.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
12.01.24	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
28.12.23	Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas (GlobeNewswire)
01.12.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
20.11.23	Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema (GlobeNewswire)
19.11.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
16.11.23	Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year (GlobeNewswire)
16.11.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
15.11.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
06.11.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
03.11.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
30.10.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
25.10.23	Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial (GlobeNewswire)
20.10.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
20.10.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
10.10.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
03.10.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ThromboGenics NV

Aktien Top/Flop

Meistgelesene Nachrichten